Roche Holding expects drugs it already has on the market and a trio of medicines due to be launched shortly to deliver sales growth for its pharmaceutical business through the end of the decade, its chief executive said.
The Swiss drugmaker's on-market pharma portfolio, together with its Gazyva drug for lupus, giredestrant for breast cancer and fenebrutinib for multiple sclerosis, should make up for any hit from generic competition until 2030, Roche Chief Executive Thomas Schinecker said at an event with investors in London on Tuesday.
The company in September said it expected its on-market pharma portfolio to deliver growth until 2028 and be stable thereafter.
"We will no longer have a situation, even with what we have in hand, where we are not going to grow," Schinecker said. "We will continue our good growth momentum not only until the end of the year, the end of the decade, but beyond."
The contribution from drug candidates in Roche's late-stage pipeline for which the company expects to release study results over the next three years will come on top, he said.
Roche's diagnostics division is expected to deliver sales growth in the mid-to-high single digit percentage range over the long term, Schinecker said.
Write to Adria Calatayud at adria.calatayud@wsj.com
Thomas Schinecker currently works at Roche Holding AG, as Chief Executive Officer from 2023, Roche Diagnostics Belgium NV, as Chief Executive Officer, Roche Holdings, Inc., as Chief Executive Officer from 2023, Roche Singapore Pte Ltd., as Chief Executive Officer from 2023, F. Hoffmann-La Roche Ltd., as Chief Executive Officer from 2023, Roche for the Trading in Medicines, Equipment, Devices & Med, as Chief Executive Officer from 2023, Genentech, Inc., as Chairman, Chugai Pharmaceutical Co., Ltd., as Director, Lucerne Festival, as Director from 2024, International Federation of Pharmaceutical Manufacturers, as President from 2025, Labor Berlin - Charité Vivantes GmbH, as Member-Innovation Board, and International Institute for Management Development, as Member-Foundation Board from 2024. Dr. Schinecker also formerly worked at Roche Diagnostics AG, as Chief Executive Officer from 2019 to 2022, Roche Diagnostics Scandinavia AB, as Chief Executive Officer, Roche Pharma (Schweiz) AG, as Chief Executive Officer in 2023, Roche Korea Co., Ltd., as Chief Executive Officer, Roche Diagnostics GmbH, as Member-Supervisory Board, and Roche Diagnostics Graz GmbH, as Head-Marketing & Sales from 2005 to 2008. Dr. Schinecker received his doctorate degree in 2003 from New York University, graduate degree in 2000 from New York University, and undergraduate degree in 1997 from Universität Salzburg.
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
